BioNexus Gene Lab Corp. Investment Income, Dividend
BioNexus Gene Lab Corp. (BGLC) reported Investment Income, Dividend of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeDividend · last filed 2026-08-14
- BioNexus Gene Lab Corp. investment income, dividend for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- BioNexus Gene Lab Corp. investment income, dividend for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- BioNexus Gene Lab Corp. investment income, dividend for the quarter ending 2025-12-31 was $360.00, a 95.75% decline year-over-year.
- BioNexus Gene Lab Corp. investment income, dividend for the quarter ending 2025-09-30 was $4.19K, a 89.20% decline year-over-year.
- BioNexus Gene Lab Corp. investment income, dividend for fiscal 2025 was $22.11K, a 67.54% decline from fiscal 2024.
- BioNexus Gene Lab Corp. investment income, dividend for fiscal 2024 was $68.13K.
| Period end | Investment Income, Dividend 3 month | Investment Income, Dividend 6 month | Investment Income, Dividend 9 month | Investment Income, Dividend 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $360.00 derived: sum of 3 quarters · filed 2026-08-14 | $4.55K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | $360.00 derived: sum of 2 quarters · filed 2026-05-15 | $4.55K derived: sum of 3 quarters · filed 2026-05-15 | $13.18K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $360.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $4.55K derived: sum of 2 quarters · filed 2026-04-14 | $13.18K derived: sum of 3 quarters · filed 2026-08-14 | $22.11K 10-K · filed 2026-04-14 |
| 2025-09-30 | $4.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $12.82K derived: sum of 2 quarters · filed 2026-08-14 | $21.75K 10-Q · filed 2025-11-14 | $30.23K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $8.63K 10-Q · filed 2026-08-14 | $17.56K 10-Q · filed 2026-08-14 | $26.04K derived: sum of 3 quarters · filed 2026-08-14 | $64.86K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $8.93K 10-Q · filed 2026-05-15 | $17.41K derived: sum of 2 quarters · filed 2026-05-15 | $56.24K derived: sum of 3 quarters · filed 2026-05-15 | |
| 2024-12-31 | $8.48K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $47.30K derived: sum of 2 quarters · filed 2026-04-14 | $68.13K 10-K · filed 2026-04-14 | |
| 2024-09-30 | $38.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $59.65K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $20.83K 10-Q · filed 2025-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |